Novartis AG ADR (NVS)vsSS Innovations International Inc. Common Stock (SSII)
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
SSII
SS Innovations International Inc. Common Stock
$3.78
-1.56%
HEALTHCARE · Cap: $788.52M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 116639% more annual revenue ($56.58B vs $48.47M). NVS leads profitability with a 23.9% profit margin vs -20.7%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
SSII
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+87.1%
Fair Value
$25.71
Current Price
$3.78
$21.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 116.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Trading at 18.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -18.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SSII
The strongest argument for SSII centers on Revenue Growth, Debt/Equity. Revenue growth of 116.8% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : SSII
The primary concerns for SSII are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a declining stock while SSII is a hypergrowth play — different risk/reward profiles.
SSII carries more volatility with a beta of 0.68 — expect wider price swings.
SSII is growing revenue faster at 116.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 22/100), backed by strong 23.9% margins. SSII offers better value entry with a 87.1% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →SS Innovations International Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
SS Innovations International, Inc., is a commercial-stage surgical robotics company in India and internationally. The company is headquartered in Gurugram, India.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?